VC: Proteon Therapeutics lands $19M in VC

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Proteon Therapeutics
Kansas City, MO

$19M
First

TVM Capital and Skyline Ventures

Proteon will use the money to hire more researchers and advance development of its dialysis therapy.

PanGenetics BV
Netherlands

€13M
Second

ABN AMRO Capital

The funds will enable PanGenetics to continue clinical development of its human CD40 antagonist, PG102, with a view to filing an IND in the first quarter of 2007.

Ingenium
Germany

€9.2M
Fourth

HBM Bioventures and TVM Capital

The funding will enable Ingenium to reach the critical next step in the development of treatments for pain and inflammatory diseases.